Impact Factor
4.41
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
7.97
2,314 total citations
h5-index
49
h5 depth signal
Cited share
90.1%
273 of 303
Total citations
2,314
Citation footprint
Metric signal
7.97
External metric anchor
Self-citation
4.5%
104 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
539
China
235
United Kingdom
125
France
110
Sweden
74
Citing Fields of Research
Neurodegenerative Disorders
1,075
Neurosciences
64
Aging & Longevity
62
Medical Ethics
60
Palliative Care
45
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
1,331
Articles tracked across the journal lifetime
Indexed publication set
303
273 cited publications
Last 12 months
245
20.4 publications/month
Open access share
98.4%
241 OA publications in the last year
Leading citing country
United States
539 citing publications
Leading citing field
Neurodegenerative Disorders
1,075 citing publications
Latest tracked publication
20 October 2026
10 recent records available
Coverage & Indexing History
v4n1, 2017-
v4n1, 2017- ; Selected citations only before this date
Active Coverage
Research Focus & Classification
Indexed Subjects
Neurodegenerative Disorders
Issuing & Sponsoring Bodies
Contributor
Clinical Trials on Alzheimer's Disease (Conference)
Broad Categories
Neurology
Neurodegenerative Disorders
MeSH Descriptors
Alzheimer Disease
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1016/j.tjpad.2026.100681
Open DOI
Cerebral microhemorrhage and cognition in preclinical Alzheimer’s disease
02
DOI 10.1016/j.tjpad.2026.100686
Open DOI
Baseline MRI markers and clinical outcomes during anti-amyloid β therapy: A real-world study in a Japanese dementia center
03
04
DOI 10.1016/s2274-5807(26)00210-4
Open DOI
Editorial Board
05
06
07
08
DOI 10.1016/j.tjpad.2026.100682
Open DOI
Frailty in the anti-amyloid era: an opportunity to individualize care
09
DOI 10.1016/j.tjpad.2026.100679
Open DOI
Feasibility of immersive 40 Hz gamma sensory stimulation in early-stage Alzheimer’s disease
10
DOI 10.1016/j.tjpad.2026.100677
Open DOI
Evoke (+) trials of semaglutide for early alzheimer’s disease: Innovations, lessons, and implications
Bibliographical & Catalog Notes
Also issued in print.